Vir Biotechnology Showcases Promising Advances in Hepatitis Treatments at J.P. Morgan Healthcare Conference
Vir Biotechnology Inc. (NASDAQ: VIR) has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference, set to take place on January 14, 2024, in San Francisco, California. Marianne De Backer, the company’s Chief Executive Officer, is slated to present at the event at 4:30 p.m. PT. Investors and stakeholders will be able to access a live webcast of the presentation, which will be available on the Vir Biotechnology corporate website for 30 days post-event. This annual conference is a key gathering for major players in the healthcare sector, serving as an important platform for bioscience companies to disclose significant developments.
In recent weeks, Vir Biotechnology has garnered attention for promising results from its clinical trials focusing on chronic hepatitis. Notably, the company released positive data from the SOLSTICE Phase 2 clinical trial, which evaluated the efficacy of tobevibart, a monoclonal antibody, administered alone and in combination with elebsiran, a small interfering RNA (siRNA) therapy, for patients with chronic hepatitis delta (CHD). The results revealed a remarkable 100% virologic response rate, along with rapid suppression of hepatitis delta virus (HDV) RNA, which underscores the potential of this combination therapy as a transformative treatment for CHD.
Moreover, Vir Biotechnology also presented compelling end-of-treatment results at The Liver Meeting, organized by the American Association for the Study of Liver Diseases (AASLD). The data from the MARCH Phase 2 clinical study further highlighted the effectiveness of tobevibart and elebsiran combinations, with or without pegylated interferon alfa (PEG-IFN), in participants with chronic hepatitis B. The findings indicated promising rates of hepatitis B surface antigen (HBsAg) loss in patients with a low baseline of HBsAg (
Comments